Mineralys Therapeutics develops lorundrostat, an oral medicine for high blood pressure that is hard to control with other treatments. MLYS reports earnings on Wed, Nov 4, 2026. In the past 30 days there were 5 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | UBS | Initiated | Hold | |
| Oct 12 | HC Wainwright & Co. | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in MLYS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLYS is in one of them and how their past MLYS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MLYS in an article yet. Here's the latest on the wider market.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company based in Radnor, Pennsylvania, that develops medicines for diseases driven by high levels of aldosterone, a hormone that affects blood pressure. Its main product candidate, lorundrostat, is a pill taken by mouth that is being developed to treat high blood pressure, especially cases that do not respond fully to other treatments. The company is also studying lorundrostat in patients with chronic kidney disease and obstructive sleep apnea. Its target patients are adults with high blood pressure, and the company has not yet sold a product.
- Headquarters
- Radnor, PA